Surgical and survival outcomes of cytoreductive surgery alone or with perioperative intraperitoneal chemotherapy in high peritoneal cancer index.

IF 0.6 Q4 SURGERY

Turkish Journal of Surgery Pub Date : 2024-09-30 eCollection Date: 2024-09-01 DOI:10.47717/turkjsurg.2024.6457

Metin Ercan, Mehmet Aziret, Kerem Karaman, Osman Köse, Volkan Öter, Hakan Yırgın, Ahmet Kaya, Yavuz Selim Kahraman, Elif Köse, Erdal Birol Bostancı, Orhan Ünal

{"title":"Surgical and survival outcomes of cytoreductive surgery alone or with perioperative intraperitoneal chemotherapy in high peritoneal cancer index.","authors":"Metin Ercan, Mehmet Aziret, Kerem Karaman, Osman Köse, Volkan Öter, Hakan Yırgın, Ahmet Kaya, Yavuz Selim Kahraman, Elif Köse, Erdal Birol Bostancı, Orhan Ünal","doi":"10.47717/turkjsurg.2024.6457","DOIUrl":null,"url":null,"abstract":"Objectives: The aim of this study was to examine the early surgical and long-term survival outcomes of cytoreductive surgery (CRS) alone and CRS plus perioperative intraperitoneal chemotherapy (IPC) in patients with peritoneal metastases (PM).Material and methods: CRS alone or CRS plus IPC was performed on 122 patients for various intraabdominal PMs. Patients were divided into two groups as PCI ≤19 and PCI >19 to compare early surgical outcomes.Results: Among PM patients 70 (57.4%) were of non-ovarian and 52 (42.6%) were of ovarian origin. Of the patients 74 (60.7%) were in the peritoneal cancer index (PCI) ≤19 group and 48 (39.3%) were in the PCI >19 group. The complication ratio of PCI >19 group was higher than that of the PCI ≤19 group and median overall survival (OS) of PCI >19 group was lower than that of the PCI ≤19 group. Complete or nearly complete (CCR-0/CCR-1) resections rates were similar in both groups (95.9% in the PCI ≤19 group and 93.8% in the PCI >19 group). However, CCR-0 resection rate was found to be lower in the PCI >19 group compared to the PCI ≤19 group (60.8% vs. 39.6%) (p <0.001).Conclusion: CCR-0/CCR-1 resections can be achieved with CRS in most patients with PCI >19 score. It would be appropriate to consider CRS or CRS plus perioperative IPC for palliative purposes in selected patients with PCI >19 score.","PeriodicalId":23374,"journal":{"name":"Turkish Journal of Surgery","volume":"40 3","pages":"219-228"},"PeriodicalIF":0.6000,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11792903/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Turkish Journal of Surgery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.47717/turkjsurg.2024.6457","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/9/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"SURGERY","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: The aim of this study was to examine the early surgical and long-term survival outcomes of cytoreductive surgery (CRS) alone and CRS plus perioperative intraperitoneal chemotherapy (IPC) in patients with peritoneal metastases (PM).

Material and methods: CRS alone or CRS plus IPC was performed on 122 patients for various intraabdominal PMs. Patients were divided into two groups as PCI ≤19 and PCI >19 to compare early surgical outcomes.

Results: Among PM patients 70 (57.4%) were of non-ovarian and 52 (42.6%) were of ovarian origin. Of the patients 74 (60.7%) were in the peritoneal cancer index (PCI) ≤19 group and 48 (39.3%) were in the PCI >19 group. The complication ratio of PCI >19 group was higher than that of the PCI ≤19 group and median overall survival (OS) of PCI >19 group was lower than that of the PCI ≤19 group. Complete or nearly complete (CCR-0/CCR-1) resections rates were similar in both groups (95.9% in the PCI ≤19 group and 93.8% in the PCI >19 group). However, CCR-0 resection rate was found to be lower in the PCI >19 group compared to the PCI ≤19 group (60.8% vs. 39.6%) (p <0.001).

Conclusion: CCR-0/CCR-1 resections can be achieved with CRS in most patients with PCI >19 score. It would be appropriate to consider CRS or CRS plus perioperative IPC for palliative purposes in selected patients with PCI >19 score.

查看原文本刊更多论文

高腹膜癌指数患者单独行细胞减少手术或围手术期腹腔内化疗的手术和生存结果。

目的：本研究的目的是探讨细胞减少手术（CRS）单独和CRS联合围手术期腹腔化疗（IPC）治疗腹膜转移（PM）患者的早期手术和长期生存结果。材料与方法：对122例不同类型的腹腔内PMs患者进行CRS单独或CRS联合IPC治疗。将患者分为PCI≤19和PCI >19两组，比较早期手术效果。结果：非卵巢系70例（57.4%），卵巢系52例（42.6%）。腹膜癌指数(PCI)≤19组74例（60.7%），PCI >19组48例（39.3%）。PCI >19组并发症发生率高于PCI≤19组，PCI >19组中位总生存期（OS）低于PCI≤19组。两组完全或接近完全（CCR-0/CCR-1）切除率相似（PCI≤19组为95.9%,PCI >19组为93.8%）。然而，与PCI≤19组相比，PCI >19组的CCR-0切除率较低（60.8%比39.6%）(p)。结论：大多数PCI >19评分的患者采用CRS可以实现CCR-0/CCR-1切除率。在PCI bbb19评分的患者中，考虑CRS或CRS加围手术期IPC作为缓解目的是合适的。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Turkish Journal of Surgery SURGERY-

CiteScore

1.20

自引率

0.00%

发文量